1. Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease

3. Program Goals

4. MM Epidemiology

5. MM Pathophysiology

6. MM Treatment Considerations and Approaches

7. MM Relapsed vs Refractory

8. RRMM When to Consider Treatment

9. RRMM Treatment Factors to Consider

10. RRMM Treatment Options

11. RRMM Case Study 1

12. Question

13. Bortezomib Management of Neuropathy

14. Case Study 1 Progressive Disease

15. Question

16. Carfilzomib Phase 2 Trial (PX-171-003-A1)

17. Phase 2 Trial (PX-171-003-A1) Efficacy

18. Carfilzomib Phase 2 Trials Grade 3/4 Toxicity (Noncardiac)

19. Carfilzomib Phase 2 Trials Cardiac Toxicity

20. Carfilzomib Management of Cardiac Events

21. RRMM Case Study 2

22. Question

23. MM-002 Phase 2 Trial Design

24. MM-002 Phase 2 Trial Outcomes

25. MM-002 Phase 2 Trial Grade 3/4 Adverse Events

26. MM-003 Phase 3 Trial Design

27. MM-003 Phase 3 Trial Outcomes

28. RRMM Case Study 3

29. Question

30. ASPIRE Phase 3 Trial Design

31. ASPIRE Phase 3 Trial Efficacy

32. ASPIRE Phase 3 Trial Grade ≥ 3 Toxicity

33. MM Selected Dose Modifications

34. MM Supportive Care

35. MM Selected Novel Agents

36. Pharmacy Perspectives in RRMM Summary

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)

40. Abbreviations (cont)

41. Abbreviations (cont)

42. References

43. References (cont)

44. References (cont)

45. References (cont)

46. References (cont)

47. References (cont)